Dr. Dipti Amin is Chief Compliance Officer for Quintiles, a role she has held since 2010. In this position she is responsible for ensuring that Quintiles remains compliant with all applicable regulatory requirements, external codes, internal Quintiles enterprise-wide policies, and expected standards of patient safety and ethics through the creation and implementation of an enterprise-wide ethics and compliance program. She reports directly to the CEO and to the Independent Director who is Chair of the Governance Committee of the Board of Directors of Quintiles.
Dr. Amin joined Quintiles in 1992 as a clinical pharmacology research physician at Guys Drug Research Unit, and has held various senior positions in Quintiles within Phase 1, Global Clinical Development Services and Late Phase. Most recently, Dr. Amin served as Quintiles Senior Vice President and Global Head of Medical and Scientific Services, Regulatory Affairs, Safety and CEVA services, Medical Writing, and Late Phase Services. In the latter role, she worked to build closer links and integration between the Clinical and Commercial businesses and developed the Real World and Late Phase business and raised its profile within Quintiles.
Educated in the United Kingdom, Dr Amin began her academic training for several professional degrees through the Guys, Kings and St Thomas’ (GKT) Medical School of the University of London. Over a 10-year period, Dr. Amin earned graduate degrees or diplomas in medicine, surgery, obstetrics and gynecology, child health, care of the elderly, General Practice and clinical pharmacology. She is licensed to practice medicine in the United Kingdom and previously in the USA as well. Her extensive clinical research work has been widely published in professional journals and textbooks, and she has presented at conferences around the world. She has taught medical students throughout her career and served on a UK Dept. of Health ethics committee for 10 years. She serves on a number of external Boards and Committees related to healthcare and the pharmaceutical industry.